CoChat

Abiraterone acetate treatment lowers 11-oxygenated androgens

Open access
Wright, Connor, O’Day, Patrick, Alyamani, Mohammed, Sharifi, Nima, Auchus, Richard J · 2020 · European Journal of Endocrinology

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancer (CRPC) and classic 21-hydroxylase deficiency (21OHD). Abiraterone, derived from the prodrug abiraterone acetate (AA), inhibits the activity of cytochrome P450 17-hydroxylase/17,20-lyase (CYP17A1), the enzyme required for all androgen biosynthesis. AA treatment effectively lowers testosterone and androstenedione in 21OHD and CRPC patients. The 11-oxygenated androgens are major adrenal-derived androgens, yet little is known regarding the effects of AA administration on 11-oxygenated androgens. Objective: To test the hypothesis that AA therapy decreases 11-oxygenated androgens. Design: Samples were obtained from 21OHD or CRPC participants in AA or AA plus prednisone (AAP)-treatment studies, respectively. Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the 11-oxygenated androgens, 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone, and 11-ketotestosterone, in plasma or serum samples from six 21OHD and six CRPC patients before and after treatment with AA or AAP, respectively. Results: In CRPC patients, administration of AAP (1000 mg/day AA with prednisone and medical castration) lowered all four 11-oxygenated androgens to below the lower limits of quantitation (<0.1–0.3 nmol/L), equivalent to 64–94% reductions from baseline. In 21OHD patients, administration of AA (100–250 mg/day for 6 days) reduced all 11-oxygenated androgens by on average 56–77% from baseline. Conclusions: We conclude that AA and AAP therapies markedly reduce the production of the adrenal-derived 11-oxygenated androgens, both in patients with high (21OHD) or normal (CRPC) 11-oxygenated androgens at baseline, respectively. Reduction of 11-oxygenated androgens is an important aspect of AA and AAP pharmacology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-19-0905

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 68

Metadata

Authors
Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J.
Affiliations
  • 1Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine
  • 3Genitourinary Malignancies Research Center, Lerner Research Institute
  • Cleveland Clinic (US)
  • University of Michigan (US)
Corresponding author
Auchus, Richard J
Venue
European Journal of Endocrinology
Published
2020-04
Volume
182
Issue
4
Pages
413-421
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W3006285711
Cited by
68
References
35
Citations by year
2026: 8 · 2025: 6 · 2024: 12 · 2023: 11 · 2022: 16 · 2021: 12 · 2020: 3
FWCI
5.92
Type
journal article
Language
en
Open access
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA190289, R01CA172382)
  • National Institute of General Medical Sciences (R01GM086596)
  • National Center for Research Resources (UL1RR024986)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
abiraterone, 11-oxygenated androgens, 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone, 11-ketotestosterone, castration-resistant prostate cancer, 21-hydroxylase deficiency, CYP17 inhibition, prednisone, androgen reduction
MeSH terms
Abiraterone Acetate, Adrenal Hyperplasia, Congenital, Adult, Androgens, Androstenes, Chromatography, Liquid, Drug Therapy, Combination, Humans, Male, Prednisone, Prostatic Neoplasms, Testosterone, Tandem Mass Spectrometry, Cytochrome P-450 Enzyme Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abiraterone acetate treatment lowers 11-oxygenated androgens. https://app.cochat.ai/papers/10.1530/eje-19-0905
The paper
Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J. (2020). Abiraterone acetate treatment lowers 11-oxygenated androgens. European Journal of Endocrinology. https://doi.org/10.1530/eje-19-0905

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.